María del Mar Álvarez-Torres

Mrs. María del Mar Álvarez-Torres


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2019 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
MÁMaría del Mar Álvarez-Torres
María del Mar Álvarez-Torres
JJJavier Juan‐Albarracín
Javier Juan‐Albarracín
EFElies Fuster-Garcia
Elies Fuster-Garcia
FBFuensanta Bellvís‐Bataller
Fuensanta Bellvís‐Bataller
DLDavid Lorente
David Lorente
JGJuan Miguel Garcia-Gomez
Juan Miguel Garcia-Gomez

6 January 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MÁMaría del Mar Álvarez-Torres
María del Mar Álvarez-Torres
EFElies Fuster-García
Elies Fuster-García
JJJavier Juan-Albarracín
Javier Juan-Albarracín
GRGaspar Reynés
Gaspar Reynés
FAFernando Aparici-Robles
Fernando Aparici-Robles
JGJuan Miguel García-Gómez
Juan Miguel García-Gómez
Background: The microvessels area (MVA), derived from microvascular proliferation, is a biomarker useful for high-grade glioma classification. Nevertheless, its measurement is costly, labor-intense, and invasive. Finding radiologic correlations with MVA could provide a complementary non-invasive approach without an extra cost and labor intensity and from the first stage. This study aims to correlate imaging markers, such as relative cerebral blood volume (rCBV), and local MVA in IDH-wildtype glioblastoma, and to propose this imaging marker as useful for astrocytoma grade 4 classification. Methods: Data from 73 tissue blocks belonging to 17 IDH-wildtype glioblastomas and 7 blocks from 2 IDH-mutant astrocytomas were compiled from the Ivy GAP database. MRI processing and rCBV quantification were carried out using ONCOhabitats methodology. Histologic and MRI co-registration was done manually with experts’ supervision, achieving an accuracy of 88.8% of overlay. Spearman’s correlation was used to analyze the association between rCBV and microvessel area. Mann-Whitney test was used to study differences of rCBV between blocks with presence or absence of microvessels in IDH-wildtype glioblastoma, as well as to find differences with IDH-mutant astrocytoma samples. Results: Significant positive correlations were found between rCBV and microvessel area in the IDH-wildtype blocks (p < 0.001), as well as significant differences in rCBV were found between blocks with microvascular proliferation and blocks without it (p < 0.0001). In addition, significant differences in rCBV were found between IDH-wildtype glioblastoma and IDH-mutant astrocytoma samples, being 2–2.5 times higher rCBV values in IDH-wildtype glioblastoma samples. Conclusions: The proposed rCBV marker, calculated from diagnostic MRIs, can detect in IDH-wildtype glioblastoma those regions with microvessels from those without it, and it is significantly correlated with local microvessels area. In addition, the proposed rCBV marker can differentiate the IDH mutation status, providing a complementary non-invasive method for high-grade glioma classification.

29 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MÁMaría del Mar Álvarez-Torres
María del Mar Álvarez-Torres
EFElies Fuster-Garcia
Elies Fuster-Garcia
Carmen BalanaCarmen Balana
Carmen Balana
Josep PuigJosep Puig
Josep Puig
JGJuan Miguel Garcia-Gomez
Juan Miguel Garcia-Gomez
In this study, we evaluated the benefit on survival of the combination of methylation of O6-methylguanine-DNA methyltransferase (MGMT) promotor gene and moderate vascularity in glioblastoma using a retrospective dataset of 123 patients from a multicenter cohort. MRI processing and calculation of relative cerebral blood volume (rCBV), used to define moderate- and high-vascular groups, were performed with the automatic ONCOhabitats method. We assessed the previously proposed rCBV threshold (10.7) and the new calculated ones (9.1 and 9.8) to analyze the association with survival for different populations according to vascularity and MGMT methylation status. We found that patients included in the moderate-vascular group had longer survival when MGMT is methylated (significant median survival difference of 174 days, p = 0.0129*). However, we did not find significant differences depending on the MGMT methylation status for the high-vascular group (p = 0.9119). In addition, we investigated the combined correlation of MGMT methylation status and rCBV with the prognostic effect of the number of temozolomide cycles, and only significant results were found for the moderate-vascular group. In conclusion, there is a lack of benefit of extending temozolomide treatment for patients with high vascular glioblastomas, even presenting MGMT methylation. Preliminary results suggest that patients with moderate vascularity and methylated MGMT glioblastomas would benefit more from prolonged adjuvant chemotherapy.

19 January 2021 in NMR in Biomedicine
Verified
Journal Article
Closed access
PDF file
MÁMaría del Mar Álvarez-Torres
María del Mar Álvarez-Torres
EFElies Fuster-Garcia
Elies Fuster-Garcia
GRGaspar Reynés
Gaspar Reynés
JJJavier Juan‐Albarracín
Javier Juan‐Albarracín
ECEduard Chelebian
Eduard Chelebian
JGJuan Miguel García‐Gómez
Juan Miguel García‐Gómez

28 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MÁMaría del Mar Álvarez-Torres
María del Mar Álvarez-Torres
Carmen BalanaCarmen Balana
Carmen Balana
EFElies Fuster-Garcia
Elies Fuster-Garcia
Josep PuigJosep Puig
Josep Puig
JGJuan Miguel Garcia-Gomez
Juan Miguel Garcia-Gomez
Background: Aberrant vascular architecture and angiogenesis are hallmarks of glioblastoma IDH-wildtype, suggesting that these tumors are suitable for antiangiogenic therapy. Bevacizumab was FDA-approved in 2009 following promising results in two clinical trials. However, its use for recurrent glioblastomas remains a subject of debate, as it does not universally improve patient survival. Purposes: In this study, we aimed to analyze the influence of tumor vascularity on the benefit provided by BVZ and propose preoperative rCBVmax at the high angiogenic tumor habitat as a predictive biomarker to select patients who can benefit the most. Methods: Clinical and MRI data from 106 patients with glioblastoma IDH-wildtype have been analyzed. Thirty-nine of them received BVZ, and the remaining sixty-seven did not receive a second-line treatment. The ONCOhabitats method was used to automatically calculate rCBV. Results: We found a median survival from progression of 305 days longer for patients with moderate vascular tumors who received BVZ than those who did not receive any second-line treatment. This contrasts with patients with high-vascular tumors who only presented a median survival of 173 days longer when receiving BVZ. Furthermore, better responses to BVZ were found for the moderate-vascular group with a higher proportion of patients alive at 6, 12, 18, and 24 months after progression. Conclusions: We propose rCBVmax as a potential biomarker to select patients who can benefit more from BVZ after tumor progression. In addition, we propose a threshold of 7.5 to stratify patients into moderate- and high-vascular groups to select the optimal second-line treatment.

17 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ECEduard Chelebian
Eduard Chelebian
EFElies Fuster-Garcia
Elies Fuster-Garcia
MÁMaría del Mar Álvarez-Torres
María del Mar Álvarez-Torres
JJJavier Juan-Albarracín
Javier Juan-Albarracín
JGJuan Miguel Garcia-Gomez
Juan Miguel Garcia-Gomez
BACKGROUND AND PURPOSE: Genetic classifications are crucial for understanding the heterogeneity of glioblastoma. Recently, MR perfusion imaging techniques have demonstrated their ability to determine molecular alterations. In this work, we investigated whether perfusion markers within infiltrated peripheral edema were associated with proneural, mesenchymal, classical and neural subtypes. MATERIALS AND METHODS: ONCOhabitats open web service was used to obtain the cerebral blood volume at the infiltrated peripheral edema for MRI studies of 50 glioblastoma patients from The Cancer Imaging Archive: TCGA-GBM. ANOVA and Kruskal-Wallis tests were carried out in order to assess the association between vascular features and the subtypes. For assessing specific differences, Mann-Whitney U-test was conducted. Finally, the association of overall survival with molecular and vascular features was assessed using univariate and multivariate Cox models. RESULTS: ANOVA and Kruskal-Wallis tests for the maximum cerebral blood volume at the infiltrated peripheral edema between the four subclasses yielded false discovery rate corrected p-values of <0.001 and 0.02, respectively. This vascular feature was significantly higher (p=0.0043) in proneural patients compared to the rest of the subtypes while conducting Mann-Whitney U-test. The multivariate Cox model pointed to redundant information provided by vascular features at the peripheral edema and proneural subtype when analyzing overall survival. CONCLUSIONS: Higher relative cerebral blood volume at infiltrated peripheral edema is associated with proneural glioblastoma subtype suggesting underlying vascular behavior related to molecular composition in that area.